Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours
The U.S. Food and Drug Administration (FDA) on Friday said that it approved Scholar Rock’s (SRRK) Isembyld, the first treatment designed to target muscle loss in spinal muscular atrophy, ahead of a September 30 deadline.The stock jumped 15% after hours at the time of writing after trading flat in t…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.